<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811369</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2008-ZAMBONEY</org_study_id>
    <nct_id>NCT00811369</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer</brief_title>
  <acronym>ZAMBONEY</acronym>
  <official_title>A Phase II, Multi-Centre, Randomized, Double-blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the combination of fulvestrant and ZACTIMA,&#xD;
      versus fulvestrant plus placebo, results in a significant decrease in the bone marker,&#xD;
      urinary N-Telopeptide (NTx) in postmenopausal women with bone only, or bone predominant,&#xD;
      hormone receptor-positive metastatic breast cancer. A significant decrease will be defined as&#xD;
      a &gt; 30% reduction in urinary NTx level from baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor angiogenesis is associated with invasiveness and the metastatic potential of various&#xD;
      cancers. Vascular endothelial growth factor (VEGF), the most potent and specific angiogenic&#xD;
      factor, regulates normal and pathologic angiogenesis. The increased expression of VEGF has&#xD;
      been correlated with metastases, recurrence and poor prognosis in many cancers. It has been&#xD;
      shown the VEGF is involved in osteolysis in women with bone metastases. ZACTIMA is an agent&#xD;
      which targets VEGF. ZACTIMA is a new agent with novel method of action - it is a VEGF&#xD;
      inhibitor, epidermal growth factor (EGFR) inhibitor, tyrosine kinase inhibitor, as well as a&#xD;
      potential RET kinase activity inhibitor.&#xD;
&#xD;
      In summary, women with bone only, or bone predominant, metastatic breast cancer is an ideal&#xD;
      group to study anti-angiogenic therapies where angiogenesis could be a major factor in tumor&#xD;
      progression and where anti-angiogenic treatment with agents like ZACTIMA could be more&#xD;
      effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant change in NTx level defined as a ≥ 30% reduction in urinary NTx level from baseline.</measure>
    <time_frame>Week # 1-4, 12, and every 12 weeks until disease progression/recurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Every 12 weeks until disease progression/recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to therapy</measure>
    <time_frame>Every 12 weeks until disease progression/recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in pain</measure>
    <time_frame>Week # 1-4, 12, and every 12 weeks until disease progression/recurrence</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant + ZACTIMA Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fulvestrant + Placebo Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant + ZACTIMA</intervention_name>
    <description>ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vandetanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant + Placebo</intervention_name>
    <description>ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal woman, defined as a woman fulfilling any one of the following criteria:&#xD;
&#xD;
               -  Age greater than or equal to 60 years or&#xD;
&#xD;
               -  Age greater than or equal to 45 years with amenorrhea more than 12 months with an&#xD;
                  intact uterus or&#xD;
&#xD;
               -  Follicle-stimulating hormone (FSH) levels in postmenopausal range or&#xD;
&#xD;
               -  Having undergone a bilateral oophorectomy&#xD;
&#xD;
          2. Metastatic breast cancer with either radiologically confirmed bone only or predominant&#xD;
             metastases to bone not considered amenable to curative treatment.&#xD;
&#xD;
          3. Evidence of hormone sensitivity either ER+ and/or PgR+, as per institutional&#xD;
             standards, in the primary tumor.&#xD;
&#xD;
          4. Patients must fulfill one of the following RECIST criteria:&#xD;
&#xD;
               -  Bone lesions, which are lytic, sclerotic or mixed (lytic + sclerotic), in the&#xD;
                  absence of measurable disease as defined by RECIST criteria or&#xD;
&#xD;
               -  Bone lesions, which are lytic, sclerotic or mixed (lytic + sclerotic), in the&#xD;
                  presence of measurable disease as defined by RECIST criteria.&#xD;
&#xD;
          5. Patients must fulfill one of the following resistances to endocrine therapy criteria:&#xD;
&#xD;
               -  Disease progression on tamoxifen or on an aromatase inhibitor as first or second&#xD;
                  line therapy for metastatic disease or&#xD;
&#xD;
               -  Development of metastatic disease while on treatment with tamoxifen or an&#xD;
                  aromatase inhibitor in the adjuvant setting or&#xD;
&#xD;
               -  Disease progression after discontinuation of prior adjuvant endocrine therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with fulvestrant or ZACTIMA.&#xD;
&#xD;
          2. History of hypersensitivity to active or inactive excipients of fulvestrant and/or&#xD;
             ZACTIMA.&#xD;
&#xD;
          3. Has received greater than one line of systemic chemotherapy for metastatic breast&#xD;
             cancer.&#xD;
&#xD;
          4. Has received chemotherapy within the past 14 days (+ 2 days).&#xD;
&#xD;
          5. Has received radiation therapy within the past 14 days (+ 2 days).&#xD;
&#xD;
          6. Has undergone major surgery within the past 21 days or has had major surgery performed&#xD;
             &gt; 21 days prior to screening and the wound remains unhealed.&#xD;
&#xD;
          7. Has received LH-RH agonist within the past 4 months.&#xD;
&#xD;
          8. Prior treatment with VEGF inhibitors (prior use of AVASTIN permitted).&#xD;
&#xD;
          9. Current or previously active systemic malignancy within 3 years prior to randomization&#xD;
             (other than breast cancer, or adequately treated in-situ carcinoma of the cervix,&#xD;
             uteri, or basal or squamous cell carcinoma of the skin).&#xD;
&#xD;
         10. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic&#xD;
             involvement, or any degree of brain or leptomeningeal involvement (past or present),&#xD;
             or symptomatic pulmonary lymphangetic spread. Patients with discrete pulmonary&#xD;
             parenchymal metastases are eligible, provided their respiratory function is not&#xD;
             compromised as a result of disease.&#xD;
&#xD;
         11. ECOG performance status of &gt; 2.&#xD;
&#xD;
         12. Currently receiving (and are unwilling to discontinue) hormone replacement therapy.&#xD;
&#xD;
         13. Laboratory results sustained at:&#xD;
&#xD;
               -  Platelets &lt; 100 x 109 /L&#xD;
&#xD;
               -  International normalized ratio (INR) &gt; 1.6&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 times normal&#xD;
&#xD;
               -  ALT or AST &gt; 2.5 times normal range if no demonstrable liver metastases or &gt; 5&#xD;
                  times normal range in the presence of liver metastases. No more than three&#xD;
                  retests within screening period are allowable.&#xD;
&#xD;
         14. Potassium level outside of normal range, despite supplementation; serum calcium (or&#xD;
             ionized or adjusted for albumin), or magnesium below the lower limit of the normal&#xD;
             range despite supplementation or creatinine clearance &lt; 30mL/min.&#xD;
&#xD;
         15. History of:&#xD;
&#xD;
               -  Bleeding diathesis (i.e. disseminated intravascular coagulation [DIC], clotting&#xD;
                  factor deficiency) or&#xD;
&#xD;
               -  Long-term anticoagulant therapy (other than anti-platelet therapy).&#xD;
&#xD;
         16. Any severe concomitant condition which makes it undesirable for the patient to&#xD;
             participate in the study or which would jeopardize compliance with the protocol, e.g.&#xD;
             severe renal or hepatic impairment or currently unstable or uncompensated respiratory&#xD;
             or cardiac conditions, ongoing or active infection, untreated primary&#xD;
             hyperparathyroidism, or psychiatric illness that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
         17. Anticipated life expectancy less than six months.&#xD;
&#xD;
         18. Non-approved/experimental drug treatment within previous 4 weeks before randomization.&#xD;
&#xD;
         19. Significant cardiovascular event (e.g., myocardial infarction, superior vena cava&#xD;
             syndrome), New York Heart Association (NYHA) classification of heart disease (Appendix&#xD;
             II) &gt; Class II within 3 months before study entry, or presence of cardiac disease that&#xD;
             in the opinion of the investigator increases the risk of ventricular arrhythmia.&#xD;
&#xD;
         20. History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is&#xD;
             symptomatic or requires treatment (NCI CTCAE Grade 3 or 4) or asymptomatic sustained&#xD;
             ventricular tachycardia. Atrial fibrillation, controlled on medication, is not&#xD;
             excluded.&#xD;
&#xD;
         21. Congenital long QT syndrome or 1st degree relative with unexplained sudden death under&#xD;
             40 years of age.&#xD;
&#xD;
         22. QT prolongation with other medications that required discontinuation of that&#xD;
             medication.&#xD;
&#xD;
         23. Presence of left bundle branch block (LBBB).&#xD;
&#xD;
         24. QTc with Bazett's correction measurable at &gt; 480msec on screening ECG. (Note: If a&#xD;
             patient has QTc &gt; 480msec on screening ECG, the screen ECG may be repeated twice (at&#xD;
             least 24 hours apart). The average QTc from the three screening ECGs must be &lt; 480msec&#xD;
             in order for the patient to be eligible for the study). Patients who are receiving a&#xD;
             drug that has a risk of QTc prolongation (see Appendix III, Table 2) are excluded if&#xD;
             QTc is &gt; 460msec.&#xD;
&#xD;
         25. Hypertension not controlled by medical therapy (systolic blood pressure &gt; 160&#xD;
             millimeter of mercury (mmHg) or diastolic blood pressure &gt; 100mmHg).&#xD;
&#xD;
         26. Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin,&#xD;
             carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function.&#xD;
&#xD;
         27. Not accessible for treatment and follow up.&#xD;
&#xD;
         28. Failure to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Clemons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Dent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odette Cancer Centre - Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSM Durham Regional Cancer Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Program of the Hôpital régional de Sudbury Regional Hospital</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre - Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De L'Universite De Montreal - Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Bone Metastases</keyword>
  <keyword>Telopeptide</keyword>
  <keyword>Zactima</keyword>
  <keyword>Fulvestrant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

